Crescent Biopharma (CBIO) Non Operating Interest Expenses (2024 - 2025)
Crescent Biopharma's (CBIO) quarterly Non Operating Interest Expenses came in at $1.1 million in Q2 2025, down 3.51% quarter-over-quarter from $1.1 million in Q1 2025.
Powered by 
Analysis
Crescent Biopharma (CBIO) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has reported Non Operating Interest Expenses for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2025.
- On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $1.1 million in Q2 2025; TTM through Mar 2026 was $1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.2 million, changed N/A from the prior year.
- Non Operating Interest Expenses was $1.1 million for Q2 2025 at Crescent Biopharma, down from $1.1 million in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $1.1 million in Q1 2025 and troughed at $852000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Crescent Biopharma | 612.02 Mn | 440.42 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 852,000.00 |